Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience Corp. has completed its second human pilot study testing different formulations of the diabetes drug, semaglutide, including a novel in-mouth dissolvable tablet. The study aims to improve the drug’s absorption and reduce side effects, with full results expected by early September. This research could revolutionize the delivery of GLP-1 drugs, which currently suffer from low absorption rates due to stomach acidity.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.